Project STRIDE

Project STRIDE was a randomized, controlled trial of buprenorphine among probationers and pre-trial defendants in the greater Washington, D.C. area who met DSM-IV criteria for opioid dependence and who were under community-based criminal justice supervision. Primary outcomes were HIV treatment (HIV-1 RNA, CD4), substance abuse treatment (time to relapse to opioid use, percent of days using opioids, percent of days abstinent from opioids, addiction severity), adverse side effects, HIV risk behavior (sexual and drug-related risks) and criminal justice (days incarcerated, retention in community supervision, rearrest) outcomes. This project was conducted in collaboration with George Mason University and Howard University.
Bio Profile

Frederick Altice, MD

Principal Investigator

Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases)

Director, Clinical and Community Research

Director, HIV in Prisons Program

Director, Community Health Care Van

Academic Icon Professor of Medicine, University of Malaya-Centre of Excellence for Research in AIDS (CERiA)

Frederick L. Altice is a professor of Medicine, Epidemiology and Public Health and is a clinician, clinical epidemiologist, intervention and implementation science researcher at Yale University School of Medicine and School of Public Health. Dr. Altice’s primary research project focuses on the interface between infectious diseases and substance use disorders and he has a special interest in Global Health. He also has a number of projects working in the criminal justice system, including...

View Full Profile

Funding provided by:
National Institute on Alcohol Abuse and Alcoholism 

Project Period:
August 1, 2010 – August 1, 2014 

Link to Report:
Project Stride at projectreporter.nih.gov